FibroGen (FGEN) Competitors $0.40 +0.05 (+13.09%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends FGEN vs. IFRX, SAVA, APLT, IVA, LPTX, RGLS, VERU, DERM, BHST, and ANROShould you be buying FibroGen stock or one of its competitors? The main competitors of FibroGen include InflaRx (IFRX), Cassava Sciences (SAVA), Applied Therapeutics (APLT), Inventiva (IVA), Leap Therapeutics (LPTX), Regulus Therapeutics (RGLS), Veru (VERU), Journey Medical (DERM), BioHarvest Sciences (BHST), and Alto Neuroscience (ANRO). These companies are all part of the "pharmaceutical preparations" industry. FibroGen vs. InflaRx Cassava Sciences Applied Therapeutics Inventiva Leap Therapeutics Regulus Therapeutics Veru Journey Medical BioHarvest Sciences Alto Neuroscience InflaRx (NASDAQ:IFRX) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations. Do insiders and institutionals hold more shares of IFRX or FGEN? 42.4% of InflaRx shares are owned by institutional investors. Comparatively, 72.7% of FibroGen shares are owned by institutional investors. 16.3% of InflaRx shares are owned by insiders. Comparatively, 2.0% of FibroGen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has preferable earnings and valuation, IFRX or FGEN? InflaRx has higher earnings, but lower revenue than FibroGen. InflaRx is trading at a lower price-to-earnings ratio than FibroGen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInflaRx$168.50K782.79-$46.18M-$1.08-2.07FibroGen$180.02M0.22-$284.23M-$1.23-0.33 Does the MarketBeat Community believe in IFRX or FGEN? FibroGen received 106 more outperform votes than InflaRx when rated by MarketBeat users. However, 64.67% of users gave InflaRx an outperform vote while only 60.35% of users gave FibroGen an outperform vote. CompanyUnderperformOutperformInflaRxOutperform Votes23864.67% Underperform Votes13035.33% FibroGenOutperform Votes34460.35% Underperform Votes22639.65% Does the media prefer IFRX or FGEN? In the previous week, FibroGen had 10 more articles in the media than InflaRx. MarketBeat recorded 15 mentions for FibroGen and 5 mentions for InflaRx. FibroGen's average media sentiment score of 0.67 beat InflaRx's score of 0.58 indicating that FibroGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InflaRx 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive FibroGen 0 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is IFRX or FGEN more profitable? FibroGen has a net margin of -67.66% compared to InflaRx's net margin of -33,362.70%. FibroGen's return on equity of 0.00% beat InflaRx's return on equity.Company Net Margins Return on Equity Return on Assets InflaRx-33,362.70% -65.98% -56.86% FibroGen -67.66%N/A -36.17% Do analysts rate IFRX or FGEN? InflaRx presently has a consensus price target of $8.00, indicating a potential upside of 257.14%. Given InflaRx's higher possible upside, research analysts clearly believe InflaRx is more favorable than FibroGen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InflaRx 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00FibroGen 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more risk and volatility, IFRX or FGEN? InflaRx has a beta of 1.67, suggesting that its stock price is 67% more volatile than the S&P 500. Comparatively, FibroGen has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. SummaryFibroGen beats InflaRx on 10 of the 18 factors compared between the two stocks. Ad Banyan Hill PublishingDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001." I put all the details together for you here — but please hurry. Get FibroGen News Delivered to You Automatically Sign up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FGEN vs. The Competition Export to ExcelMetricFibroGenPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$40.31M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-0.3310.5991.3417.19Price / Sales0.22195.381,116.63116.80Price / CashN/A57.1642.5837.86Price / Book-0.215.104.794.78Net Income-$284.23M$151.51M$120.07M$225.60M7 Day Performance20.16%-2.14%-1.90%-1.24%1 Month Performance3.31%-3.13%11.43%3.06%1 Year Performance-42.37%11.51%30.59%16.50% FibroGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FGENFibroGen2.447 of 5 stars$0.40+13.1%N/A-29.9%$40.31M$180.02M-0.33486Analyst UpgradeAnalyst RevisionNews CoverageIFRXInflaRx2.4075 of 5 stars$2.21-6.4%$8.00+262.0%+50.3%$130.13M$168,498.00-2.1960Analyst ForecastNews CoveragePositive NewsSAVACassava Sciences4.3986 of 5 stars$2.70-1.8%$111.50+4,029.6%-88.1%$129.90MN/A-1.9930News CoverageGap DownAPLTApplied Therapeutics4.5305 of 5 stars$1.11-3.5%$6.60+494.6%-70.3%$129.16M$9.99M-0.7130Analyst ForecastNews CoverageGap DownIVAInventiva3.1184 of 5 stars$2.32-5.3%$13.25+471.1%-45.3%$121.75M$15.62M0.00100LPTXLeap Therapeutics1.2971 of 5 stars$3.02+2.4%$7.50+148.3%-1.0%$115.73M$1.50M-1.5340Positive NewsGap DownRGLSRegulus Therapeutics2.7524 of 5 stars$1.67+5.4%$10.80+548.6%+20.5%$109.06MN/A-1.4830News CoveragePositive NewsVERUVeru1.9793 of 5 stars$0.74+2.4%$4.00+440.5%-3.5%$108.32M$14.09M-1.51189Earnings ReportAnalyst ForecastDERMJourney Medical2.5549 of 5 stars$5.00-1.8%$9.38+87.5%N/A$104.45M$79.18M-5.4190BHSTBioHarvest SciencesN/A$6.31+2.6%$14.00+121.9%N/A$103.64M$22.43M-4.92N/AAnalyst ForecastANROAlto Neuroscience3.2602 of 5 stars$3.84+0.3%$20.00+420.8%N/A$103.57M$210,000.000.00N/A Related Companies and Tools Related Companies InflaRx Competitors Cassava Sciences Competitors Applied Therapeutics Competitors Inventiva Competitors Leap Therapeutics Competitors Regulus Therapeutics Competitors Veru Competitors Journey Medical Competitors BioHarvest Sciences Competitors Alto Neuroscience Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:FGEN) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share FibroGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FGEN Stock Alerts